跳至主要内容
临床试验/NCT05069636
NCT05069636撤回不适用

Lymphatic Osteopathic Manipulative Medicine to Enhance COVID-19 Vaccination Efficacy

Rowan University2 个研究点 分布在 1 个国家开始时间: 2021年2月14日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
试验地点
2
主要终点
severe acute respiratory syndrome-associated coronavirus 2 (SARS-Cov-2) antibody levels

研究概览

简要总结

The purpose of this project is to study the impact of Osteopathic Manipulative Medicine (OMM) treatments, such as lymphatic myofascial release and thoracic pump techniques severe acute respiratory syndrome-associated coronavirus 2 (SARS-Cov-2) antibody levels in patients who receive the mRNA-1273 (Moderna) COVID-19 vaccine and to consider if these OMM strategies allow a stronger more robust immune response.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Inclusion criteria will include age greater than 18 years old and having safely received the COVID-19 vaccine.

排除标准

  • Exclusion criteria will include age under 18 years old, malignancy/cancer, ongoing infection, coagulopathy history, use of anticoagulant medications, and fracture or acute injury of the torso neck or upper extremities. Lymphatic OMM is safe during pregnancy and this does not need to be an exclusion criteria.

结局指标

主要结局

severe acute respiratory syndrome-associated coronavirus 2 (SARS-Cov-2) antibody levels

时间窗: The day of first vaccine dose (baseline), the day of second vaccine dose (at about 4-weeks post first vaccine dose), and 2-weeks post second vaccine dose (at about 6-weeks post first vaccine dose

Antibody levels collected via blood draw

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Lymphatic Osteopathic Manipulative Medicine to... | 临床试验